Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471175 | 0.86 | KMT2A (0.56) | KDM4EKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL267614 | 0.83 | KDM4E (0.50) | KDM4EKMT2APOLBALDH1A1MAPT | |
| SCHEMBL28788962 | 0.81 | POLB (0.52) | KDM4EKMT2APOLBALDH1A1MAPT | |
| SCHEMBL7466908 | 0.80 | KDM4E (0.68) | KDM4EKMT2APOLBALDH1A1MAPT | |
| SCHEMBL22743806 | 0.80 | SMN1; SMN2 (0.47) | KDM4EKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL27400702 | 0.80 | TSHR (0.61) | KDM4EKMT2APOLBALDH1A1HPGD | |
| SCHEMBL3471737 | 0.79 | KMT2A (0.48) | KDM4EKMT2APOLBALDH1A1MAPT | |
| SCHEMBL16533382 | 0.78 | MAPT (0.60) | KMT2AMAPTHPGDHSP90AA1CYP1A2 | |
| SCHEMBL17992557 | 0.78 | KDM4E (0.55) | KDM4EKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL24502272 | 0.77 | TDP1 (0.45) | KDM4EKMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746242-A | Synthesis method of 6, 7-substituent-4-aniline quinazoline | OMEGA CO LTD | 2012-10-24 | — | — | CN | claimed |
| CN-102746242-A | Synthesis method of 6, 7-substituent-4-aniline quinazoline | OMEGA CO LTD | 2012-10-24 | — | — | CN | disclosed |
| CN-101863844-B | Synthesis method of 6, 7-substituent-4-aniline quinazoline | XIANGZHEN BIOLOGY TECHNOLOGY CO LTD | 2012-10-03 | — | — | CN | disclosed |
| WO-2011147102-A1 | SYNTHETIC METHOD FOR 6,7-SUBSTITUENTS-4-ANILINE QUINAZOLINE | 翔真生物科技股份有限公司 (CN) | 2011-12-01 | — | — | WO | disclosed |
| US-20100267949-A1 | Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline | OMEGA MEDICAL TAIWAN LIMITED (TW) | 2010-10-21 | — | — | US | disclosed |
| CN-101863844-A | Synthesis method of 6, 7-substituent-4-aniline quinazoline | XIANGZHEN BIOLOGY TECHNOLOGY CO LTD | 2010-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267949-A1 | Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline | NQO2, ATIC, CYP3A7 | KDM4E 2145/4885KMT2A 2686/4885POLB 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.